Abstract
Importance The X chromosome has remained enigmatic in Alzheimer’s disease (AD), yet it makes up 5% of the genome and carries a high proportion of genes expressed in the brain, making it particularly appealing as a potential source of unexplored genetic variation in AD.
Objectives Perform the first large-scale X chromosome-wide association study (XWAS) of AD. Primary analyses are non-stratified, while secondary analyses evaluate sex-stratified effects.
Design Meta-analysis of genetic association studies in case-control, family-based, population-based, and longitudinal AD-related cohorts from the US Alzheimer’s Disease Genetics Consortium (ADGC) and Alzheimer’s Disease Sequencing Project (ADSP), the UK Biobank (UKB), the Finnish health registry (FinnGen), and the US Million Veterans Program (MVP). Risk for AD evaluated through case-control logistic regression analyses. Data were analyzed between January 2023 and March 2024.
Setting Genetic data available from high-density single-nucleotide polymorphism (SNP) microarrays and whole-genome sequencing (WGS). Summary statistics for multi-tissue expression and protein quantitative trait loci (QTL) available from published studies, enabling follow-up genetic colocalization analyses.
Participants 1,629,863 eligible participants were selected from referred and volunteer samples, of which 477,596 were excluded for analysis exclusion criteria. Number of participants who declined to participate in original studies was not available.
Main Outcome and Measures Risk for AD (odds ratio; OR) with 95% confidence intervals (CI). Associations were considered at X-chromosome-wide (P-value<1e-5) and genome-wide (P-value<5e-8) significance.
Results Analyses included 1,152,284 non-Hispanic White European ancestry subjects (57.3% females), including 138,558 cases. 6 independent genetic loci passed X-chromosome-wide significance, with 4 showing support for causal links between the genetic signal for AD and expression of nearby genes in brain and non-brain tissues. One of these 4 loci passed conservative genome-wide significance, with its lead variant centered on an intron of SLC9A7 (OR=1.054, 95%-CI=[1.035, 1.075]) and colocalization analyses prioritizing both the SLC9A7 and nearby CHST7 genes.
Conclusion and Relevance We performed the first large-scale XWAS of AD and identified the novel SLC9A7 locus. SLC9A7 regulates pH homeostasis in Golgi secretory compartments and is anticipated to have downstream effects on amyloid beta accumulation. Overall, this study significantly advances our knowledge of AD genetics and may provide novel biological drug targets.
Question Does the X chromosome play a role in the genetics of Alzheimer’s Disease (AD)?
Findings In a genetic meta-analysis across 1,152,284 individuals, several X chromosome loci were associated with AD. Four loci showed evidence of shared genetic associations between AD risk and regulation of nearby gene expression in brain tissue. The top association signal was intronic on SLC9A7 and linked to its expression.
Meaning We performed the first large-scale X chromosome-wide association study of AD and prioritized SLC9A7 as a novel risk locus. This study significantly advances our knowledge of AD genetics and provides novel biological drug targets.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this study was provided by the NIH (R00AG075238, M.E.B; AG060747 and AG047366, M.D.G) and the European Union[prime]s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant agreement No. 890650, Y.L.G.). JH was supported by grants from the NIH (NS108115), the Alzheimer's Association (ABA-22-970304) and the Kleberg Foundation. This study included data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration. MVP data analyses were supported by VA BLR&D grants BX004192 (MVP015; PI Logue) and BX005749 (MVP040; PI Logue). Dr. Richard Hauger was supported by MVP022 award CX001727, VISN-22 VA Center of Excellence for Stress and Mental Health (CESAMH), and National Institute of Aging R01 grants AG050595.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The current study protocol was granted an exemption by the Stanford Institutional Review Board because the analyses were carried out on de-identified, off-the-shelf data; therefore, additional informed consent was not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data used in the XWAS are available upon application to: - dbGaP (https://www.ncbi.nlm.nih.gov/gap/) - NIAGADS (https://www.niagads.org/) - LONI (https://ida.loni.usc.edu/) - AMP-AD knowledge portal / Synapse (https://www.synapse.org/) - Rush (https://www.radc.rush.edu/) - NACC (https://naccdata.org/) - UKB (https://www.ukbiobank.ac.uk/) - FinnGen (https://www.finngen.fi/en) - MVP (https://www.mvp.va.gov/) The specific data repository and identifier for ADGC and ADSP data are indicated in eTable1 of the supplement. The data, code, and phenotypes used to generate MVP results are accessible to researchers with MVP data access. Due to VA policy, MVP is currently only accessible to VA researchers with a funded MVP project, either through a VA Merit Award, career development award, or NIH R01. Additional information is available at https://genhub.va.gov/file/view/897656. GWAS summary results for the MVP cohort will be posted to dbGAP after publication. Colocalization datasets are available from: - AMP-AD knowledge portal / Synapse (https://www.synapse.org/; identifier: syn51150434) - eQTL catalogue (https://www.ebi.ac.uk/eqtl/) - GTEx (https://www.gtexportal.org/home/) Summary statistics generated by this study will be deposited in both NIAGADS and the EMBL-EBI GWAS Catalog.